NDC 17228-0324-09: candesartan cilexetil hydrochlorothiazide 32 mg; 25 mg Tablet, Drum of 30,000
This is a package of 30,000 tablets of candesartan cilexetil hydrochlorothiazide 32 mg; 25 mg Tablet from AstraZeneca AB, first listed with the FDA Dec 2012 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 17228-0324-9 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 17228 labeler · 0324 product · 9 package
- Package marketed since
- May 15, 2018
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 1722803249 3
- FDA record last changed
- Nov 5, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
This is a tablet containing two active ingredients commonly used together to help manage high blood pressure. Candesartan cilexetil is an angiotensin II receptor blocker that works by relaxing blood vessels, while hydrochlorothiazide is a diuretic that helps the body remove excess salt and water. The combination is typically used to lower blood pressure in patients whose condition is not adequately controlled by either drug alone.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 17228-0324-09 You're viewing this Main listing | 30000 TABLET in 1 DRUM | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| candesartan cilexetil hydrochlorothiazide 32 mg/1; 25 mgthis 17228-0324-09 | AstraZeneca | 30000 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from AstraZeneca AB labeler code 17228
- candesartan cilexetil 32 mg Tablet NDC 17228-0032-9
- Metoprolol succinate 50 mg Tablet, Extended Release NDC 17228-0109-1
- Metoprolol succinate 100 mg Tablet, Extended Release NDC 17228-0110-1
- Metoprolol succinate 200 mg Tablet, Extended Release NDC 17228-0111-1
- candesartan cilexetil hydrochlorothiazide 16 mg; 12.5 mg Tablet NDC 17228-0162-9
- candesartan cilexetil hydrochlorothiazide 32 mg; 12.5 mg Tablet NDC 17228-0322-9
- Selumetinib 5 mg Capsule NDC 17228-0635-0
- Selumetinib 7.5 mg Capsule NDC 17228-0640-0
- olaparib 100 mg Tablet, Film Coated NDC 17228-0668-0
- olaparib 150 mg Tablet, Film Coated NDC 17228-0679-0
- Omeprazole magnesium 20.6 mg Tablet, Delayed Release NDC 17228-0740-9
- omeprazole magnesium 20 mg Tablet, Delayed Release NDC 17228-0750-9
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: AstraZeneca AB supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |